MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna (MRNA) announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years. MRNA to Cut R&D Costs, Stops Five Pipeline Programs Management implemented a portfolio prioritization and cost efficiencies program to reduce annual research and development (R&D) expenses and focus on products that are either nearing approvals or already on the market. The firm reduced its overall R&D budget for the next four years (2025 to 2028) by nearly ...